WealthOne’s Teva Pharmaceuticals TEVA Stock Holding History

WealthOne’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-666	Closed	-$10K	–	493
2018 Q4	$10K	Buy	+666	New	+$13.7K	0.01%	373

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WealthOne's TEVA Position: Q1 2019 in Review

WealthOne sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 666 shares — an estimated $10K sold.

WealthOne first reported a position in TEVA in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

WealthOne reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
WealthOne sold 666 Teva Pharmaceuticals shares in Q1 2019, an estimated $10K.
WealthOne first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 1 quarter.
WealthOne's Teva Pharmaceuticals position peaked at $10K in Q4 2018.
522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on WealthOne's 13F filing for Q1 2019, filed 16 May 2019.